Parkinson's Disease - Market Insight, Epidemiology And Market Forecast - 2032

Parkinson's Disease - Market Insight, Epidemiology And Market Forecast - 2032

Key Highlights:

The majority of Diagnosed Prevalent Parkinson’s Disease patients were estimated in the US followed by EU4 and the UK, and Japan. The diagnosed patient of Parkinson’s disease in the US were estimated to be approximately 1.2 million in 2022.

In 2022, the market size of Parkinson’s disease was highest in the US among the 7MM accounting for approximately USD 1,820 million, and lowest in the United Kingdom with USD 135 million which is further expected to increase by 2032.

The total market size of the Parkinson’s disease treatment market is anticipated to experience growth during the forecast period (2023-2032) due to emerging treatments that includes Tavapadon (Cerevel Therapeutics), P2B001 (Pharma Two B), ABBV-951 (AbbVie), BIIB122 (Biogen), Buntanetap (Annovis Bio), IPX203 (Amneal Pharmaceuticals), NE3107 (BioVie), CVN424 (Cerevance), ITI-214 (Intra-Cellular Therapies), and CNM-Au8 (Clene Nanomedicine), among others.

Gender-specific diagnosed prevalent cases of Parkinson’s disease were higher in males (around 660 thousand cases) as compared to females (around 491 thousand) in 2022 in the US.

DelveInsight's “Parkinson’s disease - Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Parkinson’s disease, historical and forecasted epidemiology as well as the Parkinson’s disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Parkinson’s disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Parkinson’s disease market size from 2019 to 2032. The report also covers current Parkinson’s disease treatment practice/algorithm and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2019-2032

Parkinson’s disease Understanding and Treatment Algorithm

Parkinson’s disease Overview

Parkinson’s disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement.

The cause of Parkinson’s disease remains unknown but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson’s disease also have a first-degree relative with Parkinson’s disease.

Classic presenting features of Parkinson’s disease include motor symptoms, such as bradykinesia, rigidity, rest tremor, and postural instability. However, non-motor symptoms, such as depression, cognitive impairment, pain, and autonomic disturbances, are also often present and they can severely affect a patient’s quality of life

Parkinson’s disease Diagnosis

Presently, the diagnosis of Parkinson's is primarily based on the common symptoms as outlined. There is no X-ray or blood test that can confirm the disease. However, noninvasive diagnostic imaging, such as positron emission tomography (PET) can support a doctor's diagnosis.

Further details are provided in the reported

Parkinson’s disease Treatment

The treatment landscape of Parkinson’s disease consists of several medications, although none have yet reversed the effects of the disease. Levodopa is the gold standard for the treatment of motor symptoms. Further, it is common for people with Parkinson’s disease to take a variety of these medications – all at different doses and at different times of day – to manage symptoms.

The medications used to treat Parkinson’s disease include levodopa dopamine agonists MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. The main goal of these medications is to lessen motor symptoms or the symptoms that affect movement in people with Parkinson’s disease.

There are multiple dopamine agonists available in the US including ropinirole (Requip, Requip XL), pramipexole (Mirapex, Mirapex ER), rotigotine (Neupro skin patch), and apomorphine (Apokyn subcutaneous injection).

Many molecules are in the pipeline to treat Parkinson’s disease patients across the 7MM to cater to their needs. Some major products are anticipated hit the market during the study period 2019–2032, including tavapadon, P2B001, BIIB122, ABBV-951, and buntanetap.

Parkinson’s disease Epidemiology

As the market is derived using patient based model, the Parkinson’s disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Population of Parkinson’s disease, Gender-specific Diagnosed Prevalent Population of Parkinson’s disease, Age-specific Diagnosed Prevalent Population of Parkinson’s disease, and Stage-specific Diagnosed Prevalent Population of Parkinson’s disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), and the UK, and Japan from 2019 to 2032. The total diagnosed prevalent cases of Parkinson’s disease in the 7MM comprised of approximately 2.5 million cases in 2022 and are projected to increase during the forecasted period (2023-2032)

According to DelveInsight estimates, the US accounted for approximately 1.1 million diagnosed cases whereas in the EU4 and the UK, there were around 1.2 million diagnosed Parkinson’s disease cases in 2022. Japan accounted for 0.2 million diagnosed cases of Parkinson’s disease in 2022. These cases are expected to increase in the US, EU4 and the UK, and Japan by 2032

Among the EU4 and the UK, Germany had the highest diagnosed prevalent population of Parkinson’s disease (approximately 0.5 million cases), followed by France (approximately 0.2 million cases) in 2022. On the other hand, Italy had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

Parkinson’s disease has been identified as a male-dominant disease; in our analysis, the number of males suffering were higher as compared to females. In 2022, 54% cases of Parkinson’s disease were of males, while 46% cases were of females in the 7MM.

Parkinson’s disease Drug Chapters

Drug chapter segment of the Parkinson’s disease report encloses the detailed analysis of Parkinson’s disease marketed drugs and late stage pipeline drugs. It also helps to understand the Parkinson’s disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Emerging Drugs

Tavapadon: Cerevel Therapeutics/Pfizer

Cerevel Therapeutics is developing tavapadon to treat both early and late-stage Parkinson’s disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes to balance meaningful motor activity with a favorable safety profile.

In July 2020, Cerevel Therapeutics and Arya Sciences Acquisition Corp II, a special purpose acquisition company or SPAC entered into a definitive business combination agreement. Upon closing of the transaction, Arya II will redomicile as a Delaware corporation, be renamed Cerevel Therapeutics Holdings, Inc., and its common stock was expected to be listed on Nasdaq under the ticker symbol “CERE” (the “Combined Company”)

Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Accurate diagnosis, and pharmacologic treatments are all important aspects of managing Parkinson’s disease.

There are different types of medications available in market. Available medicines cannot reverse Parkinson’s disease; however, they are used to manage symptoms that affect movement in people with Parkinson’s disease. DelveInsight’s market forecast focus on the market revenue generated by pharmacological therapies (including all the currently used therapies) prescribed for the management of Parkinson’s disease and doesn’t comprise the revenue generated by devices &/or surgical procedures.

Parkinson’s disease Market Outlook

For the purpose of study, the Parkinson’s disease drugs market is categorized on the basis of medications treat Parkinson’s disease including, levodopa dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists.

In 2015, US FDA approved RYTARY for treating Parkinson’s disease. It is specifically indicated for treating Parkinson’s disease, post-encephalitic Parkinsonism, and Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. It is an extended-release oral capsule form of carbidopa/levodopa, a drug combination used for decades in its immediate-release form (Sinemet). Unlike its predecessor, with RYTARY, both immediate and extended levels of carbidopa/levodopa are found in the blood after a single dose.

In August 2017, the US FDA approved GOCOVRI (amantadine) extended-release capsules (previously ADS-5102) for treating dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.

GOCOVRI is the only medication approved by the US FDA for the treatment of dyskinesia — involuntary, jerky movements — in Parkinson’s patients who receive levodopa-based therapy, with or without accompanying dopaminergic medications.

In the emerging scenario, several companies are creating medications to serve better treatment therapies for Parkinson’s patients and are expected to enter the market including Tavapadon (Cerevel Therapeutics), P2B001 (Pharma Two B Ltd), BIIB122 (Biogen/ Denali Therapeutics), ABBV-951 (AbbVie), Buntanetap (Annovis Bio), IPX203 (Amneal Pharmaceuticals), RO7046015 (Hoffmann-La Roche), NE3107 (BioVie), CVN424 (Cerevance), CNM-Au8 (Clene Nanomedicine) and ITI-214 (Intra-Cellular Therapies, among others. They aim to investigate their products for the treatment of Parkinson’s disease.

The total market size of Parkinson’s disease in the 7MM was approximately USD 3,226 million in 2022 and is projected to increase during the forecast period (2023-2032)

The market size of Parkinson’s disease in the 7MM will increase at a CAGR of 11.2% due to the increase in diagnosed prevalent cases of the disease and the anticipated launch of emerging therapies.

Among EU4 and the UK, Germany accounts for the maximum market size in 2022 while the United Kingdom occupies the bottom of the ladder in 2022.

Parkinson’s disease Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. For example, for Tavapadon, we expect the drug uptake to be medium with a peak share of 3.7%, years to peak is expected to be 6 years from the year of launch.

Further detailed analysis of emerging therapies drug uptake in the report…

Parkinson’s disease Pipeline Development Activities

The report provides insights into different therapeutic candidates investigating the drugs in Phase III, and Phase II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Parkinson’s disease emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Parkinson’s disease evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, drug uptake along with challenges related to accessibility, include Medical/scientific writers, Medical Professors, Johns Hopkins University School of Medicine, US, Researchers from Health Economics and Outcomes Research Ltd., Cardiff, the UK, and Others.

DelveInsight’s analysts connected with 50+ KOLs to gather insights, however interviews were conducted with 15+ KOLs in the 7MM. Centers such as Parkinson’s Foundation, US, Kings College Hospital, NHS Foundation Trust, the UK, Fukuoka University, Japan etc. were contacted. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Parkinson’s disease market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, and patient burden, and competitive landscape, cost-effectiveness and geographical accessibility of therapies are provided. These pointers are based on Analyst’s discretion and assessment of the patient burden, cost analysis and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies on the basis of relevant attributes such as safety, efficacy, and frequency of administration, route of administration and order of entry. Scoring is given based on these parameters to analyze the effectiveness of a therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated, for instance, in Parkinson’s disease trials, one of the most important primary outcome measure is the time to worsening in MDS-UPDRS which provides the evaluation of the improvement.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability and the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

According to Yang et al. (2020), there were approximately 1 million individuals diagnosed with Parkinson’s disease in 2017, and a total economic burden of USD 51.9 billion. The total burden of Parkinson’s disease includes direct medical costs of USD 25.4 billion and USD 26.5 billion in indirect and nonmedical costs, including an indirect cost of USD 14.2 billion (persons with Parkinson’s disease [PWP] and caregiver burden combined), nonmedical costs of USD 7.5 billion, and USD 4.8 billion due to disability income received by PWPs. The Medicare program bears the largest share of excess medical costs, as most Parkinson’s disease patients are over age 65. The projected prevalence will be more than 1.6 million with a projected total economic burden surpassing USD 79 billion by 2037. The costs of informal caregivers comprise an important subgroup of the total costs and are often greater than direct costs. Furthermore, since most patients require informal care, these costs pose a significant burden.

The report further provides the detailed insights on the country wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out of pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs etc.

Scope of the Report

The report covers a segment of key events, executive summary, descriptive overview of Parkinson’s disease, explaining its causes, signs and symptoms, pathogenesis and currently available therapies

Comprehensive insight has been provided into the epidemiology segments and forecasts, future growth potential of diagnosis rate, disease progression along with treatment guidelines

Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies, which will have an impact on at the current treatment landscape

A detailed review of Parkinson’s disease market; historical and forecasted market size, market share by therapies, detailed assumptions and rationale behind our approach is included in the report, covering the 7MM drug outreach

The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey and treatment preference that help in shaping and driving the 7MM Parkinson’s disease market

Parkinson’s disease Report Insights

Patient Population

Therapeutic Approaches

Parkinson’s disease Pipeline Analysis

Parkinson’s disease Market Size and Trends

Existing and future Market Opportunity

Parkinson’s disease Report Key Strengths

Ten Years Forecast

The 7MM Coverage

Parkinson’s disease Epidemiology Segmentation

Key Cross Competition

Attribute analysis

Drugs Uptake and Key Market Forecast Assumptions

Parkinson’s disease Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions

Market Insights:

What was the Parkinson’s disease total market size, market size by therapies, market share (%) distribution in 2019 and how it would all look like in 2032? What are the contributing factors for this growth?

How are different therapies going to affect the treatment paradigm of Parkinson’s disease?

What kind of uptake Tavapadon (Cerevel Therapeutics), P2B001 (Pharma Two B Ltd), BIIB122 (Biogen/ Denali Therapeutics), ABBV-951 (AbbVie), Buntanetap (Annovis Bio), IPX203 (Amneal Pharmaceuticals), RO7046015 (Hoffmann-La Roche), NE3107 (BioVie), CVN424 (Cerevance), CNM-Au8 (Clene Nanomedicine) and ITI-214 (Intra-Cellular Therapies) will witness in the coming 10 years?

Which drug is going to be the largest contributor in 2032?

What are the pricing variations among different geographies for approved and other therapies?

How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of Parkinson’s disease?

How will the prevalent population of the indication change during the forecast period?

What is the historical and forecasted Parkinson’s disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

What is the prevalence rate of Parkinson’s disease and what are the evidence from literature or primary market research related to this?

What factors are affecting the increase in prevalent cases of Parkinson’s disease?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the treatment of Parkinson’s disease? What are the current treatment guidelines for the treatment of Parkinson’s disease in the US, Europe and Japan?

How many companies are developing therapies for the treatment of Parkinson’s disease

How many emerging therapies are in the mid-stage and late stage of development for the treatment of Parkinson’s disease?

What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

What are the key designations that have been granted for the emerging therapies for Parkinson’s disease?

What will be the impact of approved therapies expected patent expiry?

What is the cost burden of approved therapies on patient?

Patient acceptability in terms of preferred treatment options as per real world scenario?

What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.

What are the 7MM historical and forecasted market of Parkinson’s disease?

Reasons to buy

The report will help in developing business Parkinson’s disease Market

Insights on patient burden/disease prevalence, evolution in diagnosis and factors contributing to the change in epidemiology of the disease during the forecast years

To understand the existing market opportunity in varying geographies and the growth potential over the coming years.

Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

Detailed analysis and ranking of class-wise potential current and emerging therapies under Conjoint analysis section to provide visibility around leading classes

Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs

To understand the perspective of Key Opinion Leaders’ around the accessibility, acceptability and compliance related challenges of existing treatment to overcome barriers in future

Detailed insights on the unmet need of existing market so that the upcoming players can strengthen their development and launch strategy